Source: http://www.google.com/patents/US7820643?dq=6101531
Timestamp: 2017-05-24 16:24:49
Document Index: 97914890

Matched Legal Cases: ['Application No. 02793880', 'Application No. 02793880', 'Application No. 02793880', 'Application No. 03748971', 'Application No. 2003284005', 'Application No. 496', 'Application No. 11', 'Application No. 10', 'Application No. 11', 'Application No. 02793880', 'Application No. 02793880']

Patent US7820643 - Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inPatentsThe present invention provides a method of treating fibromyalgia syndrome (FMS), chronic fatigue syndrome (CFS), and pain in an animal subject. The method generally involves administering a therapeutically effective amount of a dual serotonin norepinephrine reuptake inhibitor compound or a pharmaceutically...http://www.google.com/patents/US7820643?utm_source=gb-gplus-sharePatent US7820643 - Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and painAdvanced Patent SearchTry the new Google Patents, with machine-classified Google Scholar results, and Japanese and South Korean patents.Publication numberUS7820643 B2Publication typeGrantApplication numberUS 10/623,431Publication dateOct 26, 2010Filing dateJul 18, 2003Priority dateNov 5, 2001Fee statusPaidAlso published asUS6602911, US6992110, US7888342, US7915246, US20030130353, US20040019116, US20040229956, US20070225375, US20080153919, US20100105778, US20100105779, US20100197796, WO2003053426A1Publication number10623431, 623431, US 7820643 B2, US 7820643B2, US-B2-7820643, US7820643 B2, US7820643B2InventorsJay D. Kranzler, Srinivas G. RaoOriginal AssigneeCypress Bioscience, Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (138), Non-Patent Citations (185), Referenced by (1), Classifications (21), Legal Events (3) External Links: USPTO, USPTO Assignment, EspacenetMethods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS4478836Jun 22, 1982Oct 23, 1984Pierre Fabre S.A.1-Aryl 2-aminomethyl cyclopropane carboxyamide (Z) derivatives and their use as useful drugs in the treatment of disturbances of the central nervous systemUS4708834May 1, 1986Nov 24, 1987Pharmacaps, Inc.Preparation of gelatin-encapsulated controlled release compositionUS4710384Jul 28, 1986Dec 1, 1987Avner RotmanSustained release tablets made from microcapsulesUS4734285Oct 28, 1985Mar 29, 1988The Dow Chemical CompanySustained release compositionsUS4740198Feb 15, 1985Apr 26, 1988Alza CorporationMethod of administering intravenous drug using rate-controlled dosage formUS4756911Apr 16, 1986Jul 12, 1988E. R. Squibb & Sons, Inc.Controlled release formulationUS4761501May 22, 1985Aug 2, 1988American Home Products CorporationSubstituted phenylacetamidesUS4775535Apr 4, 1986Oct 4, 1988Hans LoweyMethod of preparing controlled long-acting pharmaceutical formulations in unit dosage form having uniform and comparable bioavailability characteristicsUS4781919Nov 14, 1987Nov 1, 1988Schering CorporationSustained release dosage formUS4784858Aug 22, 1986Nov 15, 1988Zyma SaControlled release tabletUS4792448Jun 11, 1987Dec 20, 1988Pfizer Inc.Generic zero order controlled drug delivery systemUS4795327Mar 26, 1984Jan 3, 1989Forest Laboratories, Inc.Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactantsUS4795642Aug 17, 1987Jan 3, 1989Pharmacaps, Inc.Gelatin-encapsulated controlled-release compositionUS4795645Nov 25, 1986Jan 3, 1989Yissum Research And DevelopmentSustained release tablets of theophyllineUS4798725Jun 16, 1986Jan 17, 1989Norwich Eaton Pharmaceuticals, Inc.Sustained release capsuleUS4800083Oct 20, 1986Jan 24, 1989R. P. Scherer CorporationSustained release method and productUS4803076Sep 4, 1986Feb 7, 1989Pfizer Inc.Controlled release device for an active substanceUS4803079Dec 20, 1985Feb 7, 1989Syntex (U.S.A.) Inc.Controlled release naproxen and naproxen sodium tabletsUS4806359Apr 22, 1987Feb 21, 1989Mcneilab, Inc.Iburprofen sustained release matrix and processUS4816262Aug 28, 1986Mar 28, 1989Universite De MontrealControlled release tabletUS4820522Jul 27, 1987Apr 11, 1989Mcneilab, Inc.Oral sustained release acetaminophen formulation and processUS4822619Feb 18, 1987Apr 18, 1989Ionor, Inc.Controlled release pharmaceutical preparation containing a gastrointestinal irritant drugUS4824678Sep 5, 1985Apr 25, 1989Aktiebolaget LeoControlled-release medical preparationsUS4832957Jul 25, 1988May 23, 1989Merck & Co., Inc.Controlled release combination of carbidopa/levodopaUS4837032Feb 4, 1986Jun 6, 1989Farval AgTheophylline sustained release tabletUS4839177Dec 9, 1986Jun 13, 1989Jagotec AgSystem for the controlled-rate release of active substancesUS4842866Dec 14, 1987Jun 27, 1989Abbott Laboratories Ltd.Slow release solid preparationUS4849229Jan 5, 1988Jul 18, 1989Forest Laboratories, Inc.Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactantsUS4861590Sep 25, 1986Aug 29, 1989Colgate-Palmolive CompanySustained release fluoride and calcium compositionUS4863743Feb 19, 1986Sep 5, 1989Key Pharmaceuticals, Inc.Controlled release potassium chlorideUS4871548Apr 17, 1987Oct 3, 1989Alza CorporationControlled release dosage form comprising different cellulose ethersUS4882167Nov 24, 1987Nov 21, 1989Jang Choong GookDry direct compression compositions for controlled release dosage formsUS4891233Oct 4, 1988Jan 2, 1990The Procter & Gamble CompanyFlakes of baking shortening or lardUS4892742Nov 18, 1985Jan 9, 1990Hoffmann-La Roche Inc.Controlled release compositions with zero order releaseUS4956388Jan 12, 1990Sep 11, 1990Eli Lilly And Company3-aryloxy-3-substituted propanaminesUS5034541Dec 27, 1989Jul 23, 1991Pierre Fabre MedicamentMethod of preparing 1-phenyl-1-diethylaminocarbonyl-2-phthalimidomethyl-cyclopropane-zUS5397574Oct 4, 1993Mar 14, 1995Andrx Pharmaceuticals, Inc.Controlled release potassium dosage formUS5399359Mar 4, 1994Mar 21, 1995Edward Mendell Co., Inc.Controlled release oxybutynin formulationsUS5399362Apr 25, 1994Mar 21, 1995Edward Mendell Co., Inc.Once-a-day metoprolol oral dosage formUS5419917Feb 14, 1994May 30, 1995Andrx Pharmaceuticals, Inc.Controlled release hydrogel formulationUS5422123Sep 21, 1993Jun 6, 1995Jagotec AgTablets with controlled-rate release of active substancesUS5456921Feb 9, 1994Oct 10, 1995Labopharm, Inc.Use of cross-linked amylose as a matrix for the slow release of biologically active compoundsUS5458005Jul 15, 1993Oct 17, 1995Abbk-Flow Inc.Fluid mass flow metersUS5458887Mar 2, 1994Oct 17, 1995Andrx Pharmaceuticals, Inc.Controlled release tablet formulationUS5458888Mar 2, 1994Oct 17, 1995Andrx Pharmaceuticals, Inc.Controlled release tablet formulationUS5464633May 24, 1994Nov 7, 1995Jagotec AgPharmaceutical tablets releasing the active substance after a definite period of timeUS5472708Nov 2, 1993Dec 5, 1995Andrx Pharmaceuticals Inc.Pulsatile particles drug delivery systemUS5512297May 22, 1995Apr 30, 1996Edward Mendell Co., Inc.Sustained release heterodisperse hydrogel systems for insoluble drugsUS5532244May 17, 1995Jul 2, 1996Eli Lilly And CompanyPotentiation of drug responseUS5532250May 17, 1995Jul 2, 1996Eli Lilly And CompanyPotentiation of drug responseUS5532268May 17, 1995Jul 2, 1996Eli Lilly And CompanyPotentiation of drug responseUS5603956Jun 16, 1994Feb 18, 1997Labopharm Inc.Cross-linked enzymatically controlled drug releaseUS5621142Feb 22, 1995Apr 15, 1997Asahi Kasei Kogyo Kabushiki KaishaAminoalkylcyclopropane derivativesUS5725883Jun 7, 1995Mar 10, 1998Edward Mendell Co., Inc.Pharmaceutical excipient having improved compressibilityUS5744474Apr 20, 1995Apr 28, 1998Eli Lilly And CompanyTreatment of incontinenceUS5773025Apr 18, 1996Jun 30, 1998Edward Mendell Co., Inc.Sustained release heterodisperse hydrogel systems--amorphous drugsUS5776969Feb 27, 1997Jul 7, 1998Eli Lilly And CompanyTreatment of sleep disordersUS5792796Jun 6, 1995Aug 11, 1998Warner-Lambert CompanyMethods for treating anxiety and panicUS5824638May 22, 1995Oct 20, 1998Shire Laboratories, Inc.Oral insulin deliveryUS5834023Jul 9, 1996Nov 10, 1998Andrx Pharmaceuticals, Inc.Diltiazem controlled release formulationUS5837379Jan 31, 1997Nov 17, 1998Andrx Pharmaceuticals, Inc.Once daily pharmaceutical tablet having a unitary coreUS5885616Aug 18, 1997Mar 23, 1999Impax Pharmaceuticals, Inc.Sustained release drug delivery system suitable for oral administrationUS5897876Jun 20, 1997Apr 27, 1999Shire Laboratories Inc.Emulsified drug delivery systemUS5912013Apr 21, 1995Jun 15, 1999Shire Laboratories, Inc.Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepineUS5912256May 22, 1997Jun 15, 1999Eli Lilly And CompanyCompounds having effects on serotonin-related systemsUS5916595Dec 12, 1997Jun 29, 1999Andrx Pharmaceutials, Inc.HMG co-reductase inhibitorUS5942549Mar 4, 1997Aug 24, 1999Knoll Pharmaceutical CompanyImproving glucose toleranceUS5945416Mar 24, 1997Aug 31, 1999Eli Lilly And CompanyMethod for treating painUS5952004Mar 17, 1995Sep 14, 1999Shire Laboratories Inc.Emulsified drug delivery systemsUS6004582May 29, 1998Dec 21, 1999Laboratorios Phoenix U.S.A, Inc.Multi-layered osmotic deviceUS6028070Sep 17, 1998Feb 22, 2000Eli Lilly And CompanyTreatment of oppositional defiant disorderUS6066643Oct 9, 1998May 23, 2000Eli Lilly And CompanyPotentiation of pharmaceuticalsUS6077541Jun 18, 1999Jun 20, 2000Andrx Pharmaceuticals, Inc.Omeprazole formulationUS6096340Nov 14, 1997Aug 1, 2000Andrx Pharmaceuticals, Inc.Omeprazole formulationUS6099859Mar 20, 1998Aug 8, 2000Andrx Pharmaceuticals, Inc.Controlled release oral tablet having a unitary coreUS6099862Aug 31, 1998Aug 8, 2000Andrx CorporationOral dosage form for the controlled release of a biguanide and sulfonylureaUS6103263Nov 17, 1994Aug 15, 2000Andrx Pharmaceuticals, Inc.Delayed pulse release hydrogel matrix tabletUS6106862Aug 13, 1998Aug 22, 2000Andrx CorporationOnce daily analgesic tabletUS6110498Oct 22, 1997Aug 29, 2000Shire Laboratories, Inc.Osmotic drug delivery systemUS6184222Sep 17, 1998Feb 6, 2001Eli Lilly And CompanyTreatment of conduct disorderUS6380200Dec 1, 2000Apr 30, 2002Pfizer, Inc.Combination of aldose reductase inhibitors and selective serotonin reuptake inhibitors for the treatment of diabetic complicationsUS6395788Aug 11, 2000May 28, 2002Vela Pharmaceuticals, Inc.Methods and compositions for treating or preventing sleep disturbances and associated illnesses using very low doses of cyclobenzaprineUS6432989 *Jun 5, 2000Aug 13, 2002Pfizer IncUse of CRF antagonists to treat circadian rhythm disordersUS6441038Oct 12, 2000Aug 27, 2002Laxdale LimitedTreatment of fatigue, head injury and strokeUS6451788Aug 27, 1997Sep 17, 2002The Wwk Trust Of 225-235 High StreetTreatment of painUS6489341May 30, 2000Dec 3, 2002Sepracor Inc.Methods for the treatment of neuroleptic and related disorders using sertindole derivativesUS6500853 *Oct 11, 2000Dec 31, 2002Genetics Institute, LlcInhibitors of phospholipase enzymesUS6596900Apr 16, 2002Jul 22, 2003Pfizer IncFused bicyclic or tricyclic amino acidsUS6602911Dec 19, 2001Aug 5, 2003Cypress Bioscience, Inc.Methods of treating fibromyalgiaUS6635675Nov 5, 2001Oct 21, 2003Cypress Bioscience, Inc.Method of treating chronic fatigue syndromeUS6964962Dec 28, 2001Nov 15, 2005Pharmacia & Upjohn CompanyCombinations of reboxetine and neuroleptic agentsUS6992110Jul 18, 2003Jan 31, 2006Cypress Bioscience, Inc.Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and painUS7005452Jun 3, 2003Feb 28, 2006Pierre Fabre MedicamentUse of the dextrogyral enantiomer of milnacipran for the preparation of a drugUS20010036943Dec 18, 2000Nov 1, 2001Coe Jotham W.Pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migrainesUS20020006963Jan 29, 2001Jan 17, 2002Young James W.Method of using and compositions comprising (-) sibutramine optionally in combination with other pharmacologically active compoundsUS20020010216Feb 23, 2001Jan 24, 2002Karen RogoskyNew drug combinationsUS20020086864Jan 4, 2002Jul 4, 2002Pharmacia & Upjohn CompanyMethod of treating or preventing fibromyalgia and other somatoform disordersUS20020094986Dec 5, 2001Jul 18, 2002Pfizer IncCombination treatment for depression, anxiety and psychosisUS20020147196Apr 3, 2002Oct 10, 2002Quessy Steven NoelComposition and method for treating neuropathic painUS20020156067Dec 28, 2001Oct 24, 2002Wong Erik Ho FongNew drug combinationsUS20020187958Aug 7, 2002Dec 12, 2002Horrobin David FrederickTreatment of painUS20030013689Aug 15, 2002Jan 16, 2003Helton David ReedMethod for treating painUS20030082214Aug 17, 2001May 1, 2003Williams Robert O.Topical compositions and methods for treating painUS20030082225Oct 19, 2001May 1, 2003Mason Paul ArthurSterile, breathable patch for treating wound painUS20030130353Dec 19, 2001Jul 10, 2003Kranzler Jay D.Methods of treating fibromyalgiaUS20030143548Jan 28, 2002Jul 31, 2003Camilleri Michael L.Predicting patient responsiveness to serotonergic therapyUS20030203055Mar 17, 2003Oct 30, 2003Cypress Bioscience, Inc.Methods of treating visceral pain syndromesUS20030232805Apr 24, 2003Dec 18, 2003Cypress Bioscience, Inc.Prevention and treatment of functional somatic disorders, including stress-related disordersUS20040014739Jul 15, 2003Jan 22, 2004Koppel Gary A.Neurotherapeutic clavulanate composition and methodUS20040019116Jul 18, 2003Jan 29, 2004Cypress Bioscience, Inc.Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and painUS20040034101Jul 24, 2003Feb 19, 2004Cypress Bioscience, Inc.Treatment and prevention of depression secondary to pain (DSP)US20040063628 *May 29, 2002Apr 1, 2004New River Pharmaceuticals Inc.Active agent delivery systems and methods for protecting and administering active agentsUS20040106681Oct 3, 2003Jun 3, 2004Cypress Bioscience, Inc.Dosage escalation and divided daily dose of anti-depressants to treat neurological disordersUS20040132826Oct 22, 2003Jul 8, 2004Collegium Pharmaceutical, Inc.Modified release compositions of milnacipranUS20040228830Jan 28, 2004Nov 18, 2004Collegium Pharmaceutical, Inc.Multiparticulate compositions of milnacipran for oral administrationUS20040229956Jul 18, 2003Nov 18, 2004Cypress Bioscience, Inc.Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and painUS20050014843Nov 12, 2002Jan 20, 2005Allen Albert JohnUse of norepinephrine reuptake inhibitors for the treatment of tic disordersUS20050032782May 21, 2004Feb 10, 2005Cypress Bioscience, Inc.Treatment of chronic pain associated with drug or radiation therapyUS20050096395Feb 12, 2003May 5, 2005Rao Srinivas G.Methods of treating attention deficit/hyperactivity disorder (adhd)US20060024366Jul 29, 2005Feb 2, 2006Collegium Pharmaceutical, Inc.Modified release compositions of milnacipranUS20070072946Sep 26, 2006Mar 29, 2007Cypress Bioscience, Inc.Milnacipran for the long-term treatment of fibromyalgia syndromeUS20070225375May 22, 2007Sep 27, 2007Cypress Bioscience, Inc.Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and painUS20080034101Aug 2, 2007Feb 7, 2008Broadcom CorporationNetwork interface controller with receive side scaling and quality of serviceUS20080058317Aug 8, 2007Mar 6, 2008Cypress Bioscience, Inc.Milnacipran for the treatment of fatigue associated with fibromyalgia syndromeUS20080058318Aug 8, 2007Mar 6, 2008Cypress Bioscience, Inc.Milnacipran for the treatment of cognitive dysfunction associated with fibromyalgiaUS20080293820May 22, 2008Nov 27, 2008Cypress Bioscience, Inc.Methods for improving physical function in fibromyalgiaCA2431041A1Dec 27, 2001Jul 11, 2002Pharmacia & Upjohn CompanyNew drug combinations of norepinehrine reuptake inhibitors and neuroleptic agentsEP0759299B1Aug 16, 1996Apr 26, 2000Eli Lilly And CompanyPotentiation of serotonin responseEP0814084B1Jun 18, 1997Aug 8, 2001Eli Lilly And CompanyIndole derivative as 5-HT1A antagonist and as inhibitor of serotonine reuptakeEP0818198A1Jul 9, 1996Jan 14, 1998Lilly S.A.Potentiation of drug response by increasing serotonin availabilityFR2752732B1 Title not availableGB2362826A Title not availableWO1994000114A1Jun 22, 1993Jan 6, 1994Sepracor Inc.Methods and compositions for treating depression and other disorders using optically pure (-) sibutramineWO2000032178A2 *Dec 1, 1999Jun 8, 2000Peter Sterling MuellerUse of siburamine for the treatment of disorders of the central nervous system secondary to organic impairmentsWO2002053140A2Dec 27, 2001Jul 11, 2002Pharmacia & Upjohn CompanyNew drug combinations of norepinehrine reuptake inhibitors and neuroleptic agentsWO2003039598A1Nov 5, 2002May 15, 2003Cypress Bioscience, Inc.Selective norepinephrine serotonin reuptake inhibitors for treating fibromyalgia syndrome, chronic fatique syndrome and painWO2003068211A1Feb 12, 2003Aug 21, 2003Cypress Bioscience, Inc.Methods of treating attention deficit/hyperactivity disorder (adhd)WO2004045718A2Nov 18, 2003Jun 3, 2004Cypress Bioscience, Inc.Treatment of cognitive dysfunctions'* Cited by examinerNon-Patent CitationsReference1Aaron et al., "A review of the evidence for overlap among unexplained clinical conditions", Ann. Intern. Med. , vol. 134, No. 9.2, (2001), pp. 868-881.2Aaron et al., "Overlapping conditions among patients with chronic fatigue syndrome, fibromyalgia, and temporomandibular disorder," Arch. Intern. Med., 160: 221-227 (2000).3Advisory Action dated May 12, 2008, in U.S. Appl. No. 10/678,767, filed Oct. 3, 2003.4Alagiri et al., "Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes," Urology, 49(Suppl. 5A): 52-57 (1997).5Amendment and Response dated Mar. 18, 2009, in U.S. Appl. No. 11/835,590, filed Aug. 8, 2007.6Amendment and Response filed Apr. 6, 2009, in U.S. Appl. No. 11/835,620, filed Aug. 8, 2007.7Amendment and Response to Office Action dated Jun. 17, 2009, in U.S. Appl. No. 11/752,213, filed May 22, 2007.8Amendment and Response to Office Action dated Oct. 21, 2008, in U.S. Appl. No. 12/035,820, filed Feb. 22, 2008.9Amendment and Response to Restriction Requirement and Applicant Statement of Interview Summary dated Jun. 17, 2009, in U.S. Appl. No. 12/035,820, filed Feb. 22, 2008.10Amendment dated May 7, 2004, in European Application No. 02793880.2.11Anderberg et al., "Citalopram in patients with fibromyalgia-a randomized, double-blind, placebo-controlled study," Eur. J. Pain, 4: 27-35 (2000).12Anderberg et al., "Citalopram in patients with fibromyalgia—a randomized, double-blind, placebo-controlled study," Eur. J. Pain, 4: 27-35 (2000).13Ansari, "The efficacy of newer antidepressants in the treatment of chronic pain: a review of current literature," Harv. Rev. Psychiatry, 7: 257-277 (2000).14Applicant Statement of Interview Summary dated May 7, 2009, in U.S. Appl. No. 11/752,213, filed May 22, 2007.15Ardid, at al., "Antidepressants and pain," La Lettre de Pharmacologue 13: 8 (1993).16Atkinson et al., "Effects of noradrenergic and serotonergic antidepressants on chronic low back pain intensity," Pain, 83: 137-145 (1999).17Barkin, "The management challenges of chronic pain: the roll of antidepressants," Am. J. Ther., 7: 31-47 (2000).18Bel et al., 1999, Neropsychopharmacology 21 (6):745-754.19Bennett et al., 1988 Pain 33:87-107.20Bennett, "Pharmacological treatment of fibromyalgia," J. Functional Syndromes, 1: 79-92 (2001).21Boissevain et al., "Toward an integrated understanding of fibromyalgia syndrome. I. Medical and pathophysiological aspects", Pain, vol. 45, No. 3, (1991), pp. 227-238.22Briley, "New hope in the treatment of painful symptoms in depression," Curr. Opin. Invest. Drugs, vol. 4, No. 1, (2003), pp. 42-45. Abstract.23 *Briley, M., "Milnacipran, A Double Noradrenaline and Serotonin Reuptake Inhibiting Antidepressant," European Neuropsychopharmacology, vol. 6, Supplement 4, p. S4 (Sep. 1996).24Buskila, "Drug therapy," Baillieres Best Pract. Res. Clin. Rheumatol., 13: 479-485 (1999).25Bymaster et al., Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors.26Caccia, "Metabolism of the newer antidepressants: an overview of the pharmacological and pharmacokinetic implications," Clin. Pharmacokinet., 34: 281-302 (1998).27Carette et al., "Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia. A randomized, double-blind clinical trial," Arthritis Rheum., 37: 32-40 (1994).28Chart of Cypress Bioscience applications related to milnacipran for treatment of various disorders.29Clauw et al., "Chronic Pain and Fatigue Syndromes: Overlapping Clinical and Neuroendocrind Features and Potential Pathogenic Mechanisms," Neuroimmunomodulation, 4:134-153 (1997).30Clauw, "The pathogenesis of chronic pain and fatigue syndromes, with special reference to fibromyalgia," Med. Hypotheses, 44: 369-378 (1995).31Communication pursuant to Article 94(3) EPC dated Dec. 17, 2007, in European Application No. 02793880.2.32Communication pursuant to Article 96(2) EPC dated Jun. 1, 2005, in European Application No. 02793880.2.33Communication pursuant to Article 96(2) EPC dated Oct. 25, 2006, in European Application No. 03748971.3.34Cypress Bioscience, Inc., Investor Fact Sheet, Aug. 2001.35Decosterd et al., 2000, Pain 87:149-158.36Deprez, et al., "Which bioequivalence study for a racemic drug? Application to milnacipran," Eur. J. Drug Metab. Pharmacokinet. 23(2): 166-171(1998).37Doyle & Hu, "A new enantioselective synthesis of milnacipran and an analogue by catalytic asymmetirc cyclopropanation," Adv. Synth. Catal. 343(3):299-302 (2001).38 *DRUGU AN 1983-01770, Woerz zum Thema R, Muench.Med.Wochenschr. 124 (40) 855-56, 1982, abstract.39 *DRUGU AN 1992-39596, Moreau, G et al, Fundam.Clin.Pharmacol. 6 (4-5) 226, 1992, abstract.40Dryson, "Venflaxine and fibromyalgia," NZ Med. J. 113(1105): 87 (2000).41Dwight et al., An Open Clinical Trial of Venlafaxine Treatment of Fibromyalgia, Psychsomatics 39(1) (1998) 14-17.42Dworkin et al., "Clinical aspects of depression in chronic pain patients," Clin. J. Pain, 7: 79-94 (1991).43Eisen, "Venlafaxine therapy for vulvodynia," The Pain Clinic, 8: 365-367 (1995).44 *EMBASE AN 1998129084, Prescrire Enternational, 1998, 7/34, 51-53, abstract.45 *EMBASE AN 90228858, Macher J et al, Neuropsychobiology, 1989, 22/2, 77-82, abstract.46Examiner's first report dated Mar. 5, 2008 in Australian Application No. 2003284005.47Farthing, "Irritable bowel syndrome: new pharmaceutical approaches to treatment," Bailllieres Best Pract. Res. Clin. Gastroenterol., 13: 461-471 (1999).48Farthing, New Drugs in the Management of the Irritable Bowel Syndrome, Drugs, vol. 56, pp. 11-21, 1998.49Fennerty, Traditional Therapies for Irritable Bowel Syndrome: An Evidence-Based Appraisal, Rev. Gastroenterol. Disord., vol. 3, Suppl. 2, pp. 18-24, 2003.50Final Office Action dated Apr. 17, 2009, in U.S. Appl. No. 11/752,213, filed May 22, 2007.51Final Office Action dated Feb. 25, 2008, in U.S. Appl. No. 10/678,767, filed Oct. 3, 2003.52Final Office Action dated Jun. 4, 2009, n. U.S. Appl. No. 11/835,590, filed Aug. 8, 2007.53Final Office Action dated Mar. 4, 2009, in U.S. Appl. No. 10/678,767, filed Oct. 3, 2003.54First Examination Report for Indian Application No. 496/DELNP/2005, dated Jun. 15, 2006.55Fishbain, "Evidence-based data on pain relief with antidepressants," Ann. Med., 32: 305-316 (2000).56Fuller, Clinical Applications of 5-HT Uptake Inhibitors, Advances in the Biosciences, vol. 85, pp. 255-270, 1992.57Gendreau et al., "Efficacy of Milnacipran in Patients with Fibromyalgia," The Journal of Rheumatology, vol. 32, No. 10 (2005), pp. 1975-1984.58Giamberardino, "Recent and forgotten aspects of visceral pain," Eur. J. Pain, 3: 7-92 (1999).59Goldenberg et al., "A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia," Arthritis Rheum., 29: 1371-1377 (1986).60Goldenberg et al., "A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia," Arthritis Rheum., 39: 1852-1859 (1996).61Goodnick et al., Psychotropic Treatment of Chronic Fatigue Syndrome and Related Disorders, J. Clin. Psychiatry 54(1) (1993) 13-20.62Gruber et al., "The management of treatment-resistant depression in disorders on the interface of psychiatry and medicine," The Psychiatric Clinics of North America, 19: 351-369 (1996).63Hannonen et al., "A randomized, double-blind, placebo-controlled study of miclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder," Br. J. Rheumatol., 37: 1279-1286 (1998).64Hara, et al., The Effects of Tramadol and Its Metabolite on Glycine, -Aminobutyric AcidA, and N-Methyl-D-Aspartate Receptors Expressed in Xenopus Oocytes.65Interview Summary dated Jan. 10, 2008, in U.S. Application No. 11/752,213, filed May 22, 2007.66Jain, "Addressing both the emotional and physical symptoms in depression," Medscape CME program (2003).67Jasmin et al., 1998, Pain 75:367-382.68Jung et al., "The efficacy of selective Serotonin reuptake inhibitors for the management of chronic pain," J. Gen. Intern. Med., 12: 384-389 (1997).69Kasper et al., "A placebo-controlled study of pregabalin and venlafaxine treatment of GAD", European neuropsychopharmacology, vol. 12, Suppl. 3, (Oct. 2002), pp. S341-S342.70Kent, "SNaris, NaSSAs, and NaRls: new agents for the treatment of depression," Lancet, 355: 911-918 (2000).71Kim et al., 1992, Pain 50:355-363.72Kranzler et al., "The psychopharmacology of fibromyalgia: a drug development perspective", Psychopharmacol Bull., 36: 165-213 (2002).73Lautenschlager, "Present state of medication therapy in fibromyalgia syndrome," Scand. J. Rheumatol. Suppl., 113: 32-36 (2000).74Lecrubier, Milnacipran: The Clinical Properties of a Selective Serotonin and Noradrenaline Reuptake Inhibitor (SNRI), Human Psychopharmacol. Clin., vol. 12, pp. S127-S134, 1997.75Leventhal, "Management of fibromyalgia," Ann. Intern. Med., 131: 850-858 (1999).76Martindale, Antidepressants, Pharmaceutical Press, London, 32nd ed., pp. 271, 284, 298, 1485 (1999).77Max et al., "Effects of desipramine, amitriptyline, and fluoxetine on pain diabetic neuropathy," N. Engl. J. Med., 326: 1250-1256 (1992).78 *Medline AN 2001240387, Enggaard et al, Clin pharmacol therapeutics, Apr. 2001, 69(4) 245-51, abstract.79 *Medline AN 2001337451, Barkin et al, Am J Therapeutics, Jan. 2000, 7(1) 31-47, abstract.80 *Medline AN 97229930, Lewis et al, Am j health-system pharmacy, Mar. 15, 1997, 54(6) 643-52, abstract.81 *Medline AN 97363915, Aronson, Clin therapeutics, May-Jun. 1997, 19(3) 420-32, abstract.82Medline EMBASE 1998129084 1998 Milnacipran: New Preparation.83Mertz, Irritable Bowel Syndrome, N. Engl. J. Med., vol. 349(22), pp. 2136-2146, 2003.84Montgomery, "Venlafaxine: a new dimension in antidepressant pharmacotherapy," J. Clin. Psychiatry, 54: 119-126 (1993).85Moret et al., "Sensitivity of the response of 5-HT autoreceptors to drugs modifying synaptic availability of 5-HT", Neuropharmacology, vol. 27, No. 1, (1988), pp. 43-49.86Moret et al., 1985, Neuropharmacology 24 (12):1211-1219.87Moret et al., 1997, J. Neurochem. 69(2):815-822.88Nagaoka, et al., "Beneficial effects of a serotonin-noradrenaline reuptake inhibitor on fibromyalgia syndrome: a case report," Med. Drug. J. 37: 10 (2001).89Nicolodi et al., "Fibromyalgia and headache. Failure of serotonergic analgesia and N-methyl-d-aspartate-mediated neuronal plasticity: their common clues," Cephalalgia, Supp.21: 41-44 (1998).90Ninan, M.D., Philip T., Use of Venlafaxine in Other Psychiatric Disorders, Depression and Anxiety 12(1) (2000) 90-94.91Noguchi, at al., "Open channel block of NMDA receptors by conformationally restricted analogs of milnacipran and their protective effect against NMDA-induced neurotoxicity," Synapse 31: 87-96 (1999).92Norregaard et al., "A randomized controlled trial of citalopram in the treatment of fibromyalgia," Pain, 61: 445-449 (1995).93Novick et al., "A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation," Aliment Pharmacol. Ther., 16: 1877-1888 (2002).94Nutt et al., Potential Applications of Venlafaxine, Rev. Contemp. Pharmacother. 9 (1998) 321-331.95Office Action dated Aug. 12, 2008, in U.S. Appl. No. 11/752,213, filed May 22, 2007.96Office Action dated Aug. 22, 2008, in U.S. Appl. No. 10/678,767, filed Oct. 3, 2003.97Office Action dated Aug. 27, 2007, in U.S. Appl. No. 10/678,767, filed Oct. 3, 2003.98Office Action dated Feb. 20, 2007, in U.S. Appl. No. 10/678,767, filed Oct. 3, 2003.99Office Action dated Oct. 7, 2008, in U.S. Appl. No. 11/835,620, filed Aug. 8, 2007.100Office Action dated Sep. 18, 2008, in U.S. Patent Appl. No. 11/835,590, filed Aug. 8, 2007.101Office Action dated Sep. 22, 2008, in U.S. Appl. No. 12/035,820, filed Feb. 22, 2008.102Office Action dated Sep. 27, 2007, in U.S. Appl. No. 11/752,213, filed May 22, 2007.103O'Malley, et al., Treatment of Fibromyalgia with Antidepressants, J. Gen. Intern. Med., vol. 15, pp. 659-666, 2000.104Palmer et al., 1989, Eur J Clin Pharmacol 37:235-238.105Pande et al., "Three randomised, placebo-controlled, double-blind trials of pregabalin treatment of generalized anxiety disorder (GAD)," 10(Suppl. 3): 344 Abstract (2000).106Patel, et al., The Placebo Effect in Irritable Bowel Syndrome Trials: A Meta-Analysis, Neurogastroenterol. Motil., vol. 17, , pp. 332-340, 2005.107PCT International Preliminary Examination Report dated Feb. 5, 2004, in International Application No. PCT/US02/35396.108PCT/US02/40976 (WO 03/053426), International Preliminary Report on Patentability/Written Opinion dated Nov. 15, 2003.109PCT/US02/40976 (WO 03/053426), International Search Report dated May 2, 2003.110PCT/US03/031622 (WO 2004/030633), International Preliminary Report on Patentability/Written Opinion dated Jun. 3, 2004.111PCT/US03/031622 (WO 2004/030633), International Search Report dated Jun. 3, 2004.112PCT/US03/23088 (WO 2004/009069), International Preliminary Report on Patentability/Written Opinion dated May 3, 2005.113PCT/US03/23088 (WO 2004/009069), International Search Report dated Dec. 11, 2003.114PCT/US2006/037714 (WO 2007/038620), International Preliminary Report on Patentability/Written Opinion dated Apr. 1, 2008.115PCT/US2006/037714 (WO 2007/038620), International Search Report dated Aug. 23, 2007.116PCT/US2007/075549 (WO 2008/021932), International Preliminary Report on Patentability/Written Opinion dated Feb. 10, 2009.117PCT/US2007/075549 (WO 2008/021932), International Search Report dated Sep. 19, 2008.118PCT/US2007/075555 (WO 2008/019388), International Preliminary Report on Patentability/Written Opinion dated Feb. 10, 2009.119PCT/US2007/075555 (WO 2008/019388), International Search Report dated Sep. 12, 2008.120PCT/US2008/064471 (WO 2008/147843), International Preliminary Report on Patentability/Written Opinion dated Nov. 24, 2009.121PCT/US2008/064471 (WO 2008/147843), International Search Report dated Aug. 21, 2008.122Peghini et al., "Imipramine decreases oesophageal pain perception in human male volunteers," Gut, 42: 807-813 (1998).123Puech et al., "Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability," Int. J. Psychopharm., 12: 99-108 (1997).124Quijada-Carrera et al., "Comparison of tenoxicam and bromazepan in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial," Pain, 65: 221-225 (1996).125Quintero et al., 2000, Pharmacology, Biochemistry and Behavior 67:449-458.126Rao et al., "Pharmacological therapies in fibromyalgia," Best Prod. Res. Clin. Rheumatol., 17: 611-627 (2003).127Rao et al., The neuropharmacology of centrally-acting analgesic medications in fibromyalgia, Theum. Dis. Clin. N. Am. 28 (2002) 235-259.128Reid et al., 2000, British Medical Journal 320:292-296.129Reimann et al., Interaction of the Central Analgesic, Tramadol, with the Uptake and Release of 5-hydroxytryptamine in the rat brain in vitro, Br J Pharmacol. Jan. 1992; 105(1):147-51.130Reimann, et al., Effects of the Central Analgesic Tramadol on the Uptake and Release of Noradrenaline and dopamine in vitro, Br J Pharmacol. Mar. 1993; 108(3):806-11.131Reneric et al., "Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test," Psychopharmacology, 136: 190-197 (1998).132Response to Final Office Action Under 37 C.F.R. 1.116 dated Apr. 15, 2008, in U.S. Appl. No. 10/678,767, filed Oct. 3, 2003.133Response to Office Action dated Dec. 12, 2008, in U.S. Appl. No. 11/752,213, filed May 22, 2007.134Response to Office Action dated Dec. 27, 2007, in U.S. Appl. No. 11/752,213, filed May 22, 2007.135Response to Office Action Under 37 C.F.R. 1.111 dated Jun. 7, 2007, in U.S. Appl. No. 10/678,767, filed Oct. 3, 2003.136Response to Office Action Under 37 C.F.R. 1.111 dated Nov. 24, 2008, in U.S. Application No. 10/678,767, filed Oct. 3, 2003.137Response to Office Action Under 37 C.F.R. 1.111 dated Nov. 27, 2007, in U.S. Appl. No. 10/678,767, filed Oct. 3, 2003.138Response to Restriction Requirement dated Mar. 4, 2008, in U.S. Application No. 11/752,213, filed May 22, 2007.139Response to Restriction Requirement dated Nov. 16, 2006, in U.S. Appl. No. 10/678,767, filed Oct. 3, 2003.140Response with amended claims dated Jun. 17, 2008, in European Application No. 02793880.2.141Response with amended claims dated Nov. 24, 2005, in European Application No. 02793880.2.142Restriction Requirement dated Feb. 4, 2008, in U.S. Appl. No. 11/752,213, filed May 22, 2007.143Restriction Requirement dated Feb. 4, 2009, in U.S. Appl. No. 12/035,820, filed Feb. 22, 2008.144Restriction Requirement dated Oct. 20, 2006, in U.S. Appl. No. 10/678,767, filed Oct. 3, 2003.145Ruoff, "Depression in the patient with chronic pain," The Journal of Family Practice, 43: S25-S33 (1996).146Sanchez et al., 1999, Cellular and Molecular Neurobiology 19(4):467-489.147Saper et al., "Nefazodone for chronic daily headache prophylaxis: an open-label study," Headache, 41: 465-474 (2001).148Seltzer et al., 1990, Pain 43:205-218.149Shuto et al., "Synthesis of (+) and (-) milnaciprans and their conformationally restricted analogs," Tetrahedron Lett., 37: 641-644 (1996).150Shuto et al., "Synthesis of (+) and (−) milnaciprans and their conformationally restricted analogs," Tetrahedron Lett., 37: 641-644 (1996).151Shuto, at al., "Synthesis and biological activity of conformationally restricted analogs of milnacipran: (lS,2R)-1-(phenyl-2-[(S)-1aminopropyl]-N,N-diethylcyclopropenecarboxamide, an efficient noncompetitive N-methyl-D-aspartic acid receptor antagonist," J. Med. Chem. 39: 4844-4852 (1996).152Shuto, et al., "(±)-Z-2-(Aminomethyl)-1-phenylcyclopropanecarboximide derivatives as a new prototype of NMDA receptor antagonists," J. Med. Chem. 38: 2964-2968 (1995).153Shuto, et al., "(1S,2R)-1-(phenyl-2-[(s)-1-aminopropyl]-N,N-diethylcyclopropanecarboxamide (PPDC), a new class of NMDA-receptor antagonist: molecular design by a novel conformational restriction strategy," Jpn. J. Pharmacol. 85: 207-213 (2001).154Shuto, et al., "Synthesis and biological activity of conformationally restricted analogues of milnacipran: (1S,2R)-1-phenyl-2-[(r)-1-amino-2-propynyl]-N,N-diethylcyclopropane-carboximide is a novel class of NMDA receptor channel blocker," J. Med. Chem. 41: 3507-3514 (1998).155Sindrup et al., "Efficacy of pharmacological treatment of neuropathic pain: an update and effect related to mechanism of drug action," Pain, 83: 389-400 (1999).156Spencer and Wild, 1998, supra.157Swaynok et al., "Peripheral antinociceptive actions of desipramine and fluoxetine in an inflammatory and neuropathic pain test in the rat," Pain, 82: 149-158 (1999).158Tatsumi et al., 1997, European Journal of Pharmacology 340:249-258.159Thema, "The drug induced alleviation of carcinoma pain," Much. Med. Wochenschr , 124:855-856 (1982).160Turcotte et al., 2001, Neuropsychopharmacolgy 24(5):511-521.161U.S. Appl. No. 10/678,767, filed Oct. 3, 2003, by Srinivas G. Rao et al.; Amendment accompanying request for continued examination dated Sep. 3, 2009.162U.S. Appl. No. 10/678,767, filed Oct. 3, 2003, by Srinivas G. Rao et al.; Non-Final Office Action dated Jan. 8, 2010.163U.S. Appl. No. 11/535,237, filed Sep. 26, 2006, by Srinivas G. Rao et al.; Non-Final Office Action dated Mar. 3, 2010.164U.S. Appl. No. 11/535,237, filed Sep. 26, 2006, by Srinivas G. Rao et al.; Restriction Requirement dated Oct. 23, 2009.165U.S. Appl. No. 11/752,213, filed May 22, 2007, by Jay D. Kranzler et al.; Non-Final Office Action dated Jun. 25, 2009.166U.S. Appl. No. 11/835,620, filed Aug. 8, 2007, by Srinivas G. Rao et al.; Final Office Action dated Jul. 2, 2009.167U.S. Appl. No. 12/035,820, filed Feb. 22, 2008, by Jay D. Kranzler et al.; Final Office Action dated Nov. 27, 2009.168U.S. Appl. No. 12/125,302, filed May 22, 2008, by Srinivas G. Rao et al.; Non-Final Office Action dated Nov. 23, 2009.169Vaishnavi et al., "Milnacipran: A comparative analysis of human monoamine uptake and transporter binding affinity," Biol Psychiatry, 55: 320-322 (2004).170Viazzo et al., 1996, Tetrahedron Lett. 37(26):4519-4522.171Vitton et al., "A double-blind placebo-controlled trial of milnacipran in the treatment of fibromyalgia," Hum Psychopharmacol Clin Exp, 19: S27-S35 (2004).172Watson et al., "Amitriptyline versus maprotiline in postherpetic neuralgia: a randomized, double-blind, crossover trial," Pain, 48: 29-36 (1992).173Wesselman, "Interstitial cystitis: A chronic visceral pain syndrome," Urology, 57(Suppl. 64): 32-39 (2001).174Wessely et al., "Functional somatic syndromes: one or many?," Lancet; 354: 936-939 (1999).175Witter et al., "Chronic pain and fibromyalgia: the regulatory perspective", Best Practice Res Clin Rheumatology, vol. 17, No. 4, (2003), pp. 541-546.176Wolfe et al., "A double-blind Placebo Controlled Trial of Fluoxetine in Fibromyalgia", Scand. J. Rheum., vol. 23, No. 5, (1994), pp. 255-259.177Wolfe et al., "A double-blind placebo controlled trial of fluoxetine in fibromyalgia," Scand. J. Rheum., 23: 255-259 (1994).178Wolfe et al., "Health Status and Disease Severity in Fibromyalgia: Results of a Six-Center Longitudinal Study", Arthritis Rheum., vol. 40, No. 9, (1997), pp. 1571-1579.179Wolfe et al., "Preference of Nonsteroidal Antiinflammatory Drugs Over Acetaminophen by Rheumatic Disease Patients", Arthritis Rheumatism, vol. 43, No. 2, (2000), pp. 378-385.180Wolfe et al., "The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia", Arthritis Rheumatism, vol. 33, No. 2 (1990) pp. 160-172.181Wolfe et al., "The Prevalence and Characteristics of Fibromyalgia in General Population", Arthritis Rheumatism, vol. 38, No. 1 (1995) pp. 19-28.182Woolf et al., "Neuropathic pain: aetiology, symptoms, mechanisms, and management," Lancet, 353: 959-1964 (1999).183Yoshimura et al., "The involvement of the tetrodotoxin-resistant sodium channel Nav1.8 (PN3/SNS) in a rat model of visceral pain", J. Neurosci., vol. 21, No. 21, (2001), pp. 8690-8696.184Yunus et al., "Towards a model of pathophysiology of fibromyalgia: aberrant central pain mechanisms with peripheral modulation," J. Rheumatol., 19: 846-850 (1992).185Zelter et al., 2000, Pain 89:19-24.* Cited by examinerReferenced byCiting PatentFiling datePublication dateApplicantTitleUS20100286260 *May 5, 2010Nov 11, 2010Forest Laboratories Holdings Ltd.Milnacipran formulations* Cited by examinerClassifications U.S. Classification514/183, 514/617, 514/210.12, 514/385, 514/252.01, 514/579International ClassificationA61P25/00, A61K31/50, A61K31/135, A61K9/00, A61K31/00, A61K31/165, A61K31/33, A61K31/16, A61K31/415Cooperative ClassificationA61K31/00, A61K31/165, A61K31/135European ClassificationA61K31/135, A61K31/165, A61K31/00Legal EventsDateCodeEventDescriptionJul 28, 2013ASAssignmentOwner name: ROYALTY PHARMA COLLECTION TRUST, NEW YORKFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SAVELLA AIV LLC;REEL/FRAME:030890/0673Effective date: 20110406Owner name: SAVELLA AIV LLC, NEW YORKFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CYPRESS BIOSCIENCE, INC.;REEL/FRAME:030890/0665Effective date: 20110316Apr 28, 2014FPAYFee paymentYear of fee payment: 4Mar 21, 2017ASAssignmentOwner name: FOREST LABORATORIES HOLDINGS LIMITED, BERMUDAFree format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ROYALTY PHARMA COLLECTION TRUST;REEL/FRAME:041668/0583Effective date: 20170207RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services